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Abstract 28 
Obstructive sleep apnoea (OSA) is a common disorder that is associated with serious co-morbidities 29 
with a negative impact on quality of life, life expectancy and health costs. As OSA is related to obesity 30 
and is associated with sleep disruption, increased inflammation and oxidative stress, it is not 31 
surprising that OSA has an impact on the secretion of multiple hormones and is implicated in the 32 
development of many endocrine conditions. On the other hand, many endocrine conditions that can 33 
affect obesity and/or upper airways anatomy and stability have been implicated in the development 34 
or worsening of OSA. This bi-directional relationship between OSA and the endocrine system has 35 
been increasingly recognised in experimental and epidemiological studies and there are an increasing 36 
number of studies examining the effects of OSA treatment on endocrine conditions and vice-versa. In 37 
this review article, we will critically appraise and describe the impact of OSA on the endocrine system 38 
including obesity, dysglycaemia, the pituitary, the thyroid, the adrenals, the reproductive system and 39 
the bones. In each section, we will assess whether a bi-directional relationship exists, and we will 40 
describe the potential underlying mechanisms. We have focused more on recent studies and 41 
randomised controlled trials where available and attempted to provide the information within clinical 42 
context and relevance.  43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
Introduction:  54 
Obstructive Sleep Apnoea (OSA) is a common disorder that affects 13-33% of men and 6-19% of 55 
women1. OSA is characterized by instability in the upper airways (UAs) leading to recurrent episodes 56 
of the UA obstruction, particularly during the transition to sleep and rapid-eye-movement (REM) 57 
sleep (characterised by low-amplitude, mixed-frequency theta EEG waves, pronounced eye activity 58 
and low muscle tone2) (see online supplement)3-6. These repeated obstructions are associated with 59 
recurrent episodes of oxygen desaturation/ re-saturation, cyclical changes in blood pressure (BP), 60 
heart rate, sympathetic activity, and intrathoracic pressure, brief microarousals and changes to sleep 61 
architecture, such as the loss of REM and slow wave sleep ( SWS or deep sleep,  is stage N3 of NREM 62 
sleep characterised by high-amplitude slow waves, further decrease in muscle tone, possible eye 63 
movement cessation and is a restorative sleep stage decreasing though with age2) (Figure 1 & online 64 
supplement) 3, 5, 7.  65 
The interactions between OSA and the endocrine system have attracted much attention and they 66 
often can be bi-directional, which is not surprising considering the diurnal secretion pattern of many 67 
hormones. In addition, OSA treatment (namely continuous positive airway pressure CPAP) has an 68 
impact on the endocrine system (such as insulin resistance, cortisol secretion) while treating 69 
endocrine disorders (such as obesity, hypothyroidism, or acromegaly) can also improve OSA. 70 
Moreover, the well-established higher OSA risk in men vs. women also emphasises the potential 71 
relationship between sex hormones and OSA pathogenesis. Hence, it is important to understand the 72 
links between OSA and the endocrine/metabolic system in order to improve our understanding of the 73 
pathogenesis and the comorbidities and mortality associated with OSA and a variety of endocrine 74 
disorders8.  75 
In this article, we will review the interactions between OSA and the endocrine system and we will 76 
highlight the underlying mechanisms underpinning this bidirectional relationship when exists, as well 77 
as explore the potential impact of OSA treatment on the endocrine disorders and vice versa. Some 78 
aspects of this article require some understanding of the pathogenesis of OSA, hence we have 79 
provided an overview of OSA and its pathogenesis in the online supplement. 80 
OSA & Obesity Interplay 81 
Obesity is a major risk factor for the development of OSA9-11, which is driving the increase in OSA 82 
prevalence1, 12. Obesity prevalence in patients with OSA (approx. 70%)  is also higher than that of the 83 
general population13.  84 
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The impact of weight change on OSA 85 
Weight changes have significant impact on OSA and its severity. In a longitudinal study of randomly 86 
selected patients from Wisconsin, a 10% weight gain over 4 years was associated with 32% (95%CI 20-87 
45%) increase in the Apnoea- Hypopnoea Index (AHI: the average number of apnoea and hypopnea 88 
events per hour of sleep)  and 6-fold higher risk of developing moderate to severe OSA (95%CI 2.2-17) 89 
compared to weight stability11. On the other hand, 10% weight loss was associated with 26% (95%CI 90 
18-34%) decrease in the AHI compared to weight stability11, partly due to a reduction in UAs 91 
collapsibility observed with weight loss14. The favourable impact of weight loss on OSA and its 92 
severity seems to be evident regardless of the method of losing weight such as life-style 93 
interventions, pharmacotherapy, or bariatric surgery as has been shown by several studies among 94 
them and randomized controlled trials (RCTs)14-18. 95 
 In a RCT, of 60 patients with obesity and moderate to severe OSA, laparoscopic adjustable gastric 96 
banding (LAGB) resulted in greater weight loss (5.1 vs. 27.8 kg), and greater reductions in AHI (based 97 
on PSG) (-14.0 vs. -25.5 events/hour; between-group difference was -11.5 events/h 95% CI -28.3 to 98 
5.3; P = 0.18) over 2 years compared to life-style intervention (dietary, physical activity and behavioral 99 
conventional program)15. In a recent post-hoc analysis of this RCT, patients who achieved a normal 100 
supine AHI (i.e. AHI < 5/h) lost significantly more weight than those who had persistently elevated AHI 101 
(weight change −23.0 [−21.0 to −31.6]% vs. −6.9 [-1.9 to −17.4]%, p = 0.001)19. Other studies also 102 
showed significant improvements in the AHI and a high proportion of OSA resolution following sleeve 103 
gastrectomy and gastric bypass16, 17. A meta-analysis confirmed the positive impact of bariatric 104 
surgery on OSA severity, by showing a significant reduction of AHI post-surgery (by 38.2 events/hour, 105 
95% CI: 31.9-44.4)20. A more recent systematic review and meta-analysis by Wong et al showed that 106 
bariatric surgery was associated with a reduction in the AHI (WMD -25.1 events/h 107 
(95%CI −29.9, −20.2)); with the pooled mean pre- and post-surgery AHI of 39.3 ± 15.1 and 12.5 ± 5.6 108 
events/h respectively; however OSA persisted in most patients and there was high between studies 109 
heterogeneity mostly due to baseline AHIO and duration of follow up21. Hence, RCTs remain needed 110 
to address the impact of bariatric surgery on OSA, although these might be challenging to conduct. In 111 
another RCT, liraglutide 3mg daily combined with lifestyle intervention resulted in greater reductions 112 
in weight (-5.7% vs -1.6%, P<0.0001) and AHI (-12.2 vs -6.1 events/h, estimated treatment difference: 113 
-6.1 events/h; 95% CI -11.0 to -1.2, P=0.015) compared to life-style intervention only over 32 weeks18. 114 
The degree of weight loss correlated significantly with improvements in OSA in this trial18.  115 
Obesity can affect multiple aspects of OSA pathogenesis, as summarised in Figure 222-36 .   116 
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The impact of OSA on weight (Figure 2B) 117 
The impact of OSA on obesity is controversial. One possibility is that OSA could lead to worsening 118 
obesity via multiple mechanisms such as increased excessive daytime sleepiness (EDS) leading to a 119 
reduction in physical activity, sleep disruption leading to changes in hunger and satiety hormones37-39 120 
(leptin resistance, increased ghrelin, increased orexin, and neuropeptide Y levels), changes to sleep 121 
duration and architecture40-44  . Sleep restriction was associated with increased activation of the brain 122 
regions related to emotional response to stimuli and motivation and reward system based on 123 
functional MRI, which was similar to what observed following energy deprivation resulting in 124 
corrective behavior of seeking food45, 46. This is supported by cross-sectional studies showing that the 125 
AHI was significantly associated with increased preference of calorie-dense foods independent of the 126 
severity of obesity in adolescents and children47, 48 and that visceral obesity was increased in  patients 127 
with OSA and short sleep duration (< 5 h/night) (OR, 4.40, 95% CI, 1.80-10.77), compared to those 128 
who slept ≥ 7 h/night49. In addition, disruption of sleep architecture (suppression of SWS as happens 129 
in OSA) without affecting sleep duration in young healthy men, increased hunger for high-calorie food 130 
in the afternoon and evening50. OSA could also contribute to increased fat mass by activation of the 131 
HPA axis and increased cortisol secretion and by hypercapnia induced adipogenesis OSA could also 132 
cause obesity via increased cortisol secretion51 and hypercapnia induced adipogenesis52. However, 133 
despite the above mentioned plausible mechanisms, epidemiological evidence for an impact of OSA 134 
on weight longitudinally is lacking. One small (n=53) prospective study of patients with newly 135 
diagnosed OSA showed 7.4±1.5 kg weight-gain over 12 months, but these patients had also a history 136 
of weight gain in the year preceding OSA diagnosis53, hence quantifying the impact of OSA is difficult 137 
without an appropriate control group.  138 
Nonetheless, if OSA is a cause of obesity, then it would be expected that OSA treatment will lead to 139 
weight loss. However, a systematic review of 3181 patients from 25 RCTs showed that CPAP resulted 140 
in a modest but statistically significant increase in BMI and weight compared to control (BMI change: 141 
−0.018±0.243 kg/m2  for controls vs. 0.134±0.273 kg/m2  for CPAP; weight change: −0.096±0.718 kg 142 
for controls vs. 0.417±0.718 kg for CPAP)54. The mechanisms behind the weight gain after CPAP are 143 
not fully elucidated. However, CPAP reduces leptin (satiety hormone), intermittent hypoxia and 144 
sympathetic activity leading to reductions in lipolysis and energy expenditure and hence can cause 145 
weight gain55-61. 146 
Furthermore, it is plausible that OSA can lead to weight loss via increased sympathetic activity leading 147 
to increased energy expenditure and lipolysis via lipoprotein lipase inhibition and sympathetic 148 
activation62, 63. The net effects of the above-mentioned opposing mechanisms/impacts of weight gain 149 
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and weight loss is potentially weight maintenance in patients with OSA. CPAP treatment tilts the 150 
balance between these opposing mechanisms towards weight gain by inhibiting sympathetic activity 151 
(Figure 2), but this might be opposed to a certain degree by the impact of CPAP on increasing GH 152 
levels leading to lipolysis64. The above, however, is only a hypothesis that requires further 153 
investigations.”It is plausible that OSA might have multifaceted effects that can promote weight gain 154 
and weight loss resulting in largely opposing effects and when patients receive CPAP then the balance 155 
is tilted towards weight gain (Figure 2). This is, however, a hypothesis that needs to be examined. 156 
OSA & Dysglycaemia 157 
As obesity is a major risk factor for OSA, much of the research in this field has focused on pre-158 
diabetes/T2D. However, it is now increasingly recognized that OSA is common in patients with T1D as 159 
well. In this section, we will focus mostly on pre-diabetes/T2D but we will also summarise the 160 
evidence regarding T1D. 161 
Epidemiology: 162 
In general population studies, OSA has been shown to be associated with various comorbidities, 163 
including T2D9, which is not surprising since obesity is a common risk factor for OSA and T2D7, 65. 164 
Several cross-sectional studies showed a high prevalence of OSA (mild: 5 ≤ AHI < 15; moderate: 15 ≤ 165 
AHI < 30; severe: AHI ≥ 30) in patients with T2D (8.5-86%, 23.8-70% moderate-to-severe OSA), and a 166 
high prevalence of T2D in patients with OSA (15-30%)7, 66. This variation in prevalence estimates is due 167 
to different diagnostic methods and criteria used to define OSA and differences in studies 168 
populations67-71.  169 
Longitudinal studies have also shown that OSA is an independent risk factor for the development of 170 
T2D. A recent meta-analysis of 8 studies (63,647 participants) showed that OSA was an independent 171 
risk factor for T2D after adjustment for age, sex, and BMI (adjusted  RR 1.49, 95% CI:1.27, 1.75), which 172 
remained significant even in studies that defined OSA as AHI ≥ 5 (adjusted RR 1.42; 95% CI 1.02, 173 
1.99)72. A small RCT of 12 weeks in 80 patients with obesity (BMI > 45 kg/m2 and mostly with 174 
metabolic syndrome) suggested that CPAP resulted in improvements in impaired glucose tolerance 175 
status compared to no CPAP and that CPAP lowered the 2-h glucose levels following OGTT 73. 176 
However, there remains a need for large RCTs of long duration to assess the impact of CPAP, on its 177 
own or in combination with lifestyle intervention, on T2D prevention. 178 
OSA and insulin resistance and β-cell function:  179 
The impact of OSA on incident T2D is likely to be mediated by the effects of OSA on insulin resistance 180 
(IR) and β-cell dysfunction7. Studies that examined the relationship between OSA and IR had 181 
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conflicting results, due to variations in the definitions of OSA and IR, but most of the studies showed 182 
an association65. The association between OSA and IR was present in lean men, suggesting that the 183 
relationship is not dependant on obesity74, 75. Variation in EDS might contribute to the variation in the 184 
associations between IR and OSA observed in the different studies as Barcelo et al showed that the 185 
association between OSA and IR was only evident in patients with EDS vs. without EDS despite being 186 
matched for BMI76. In support of the relationship between OSA and IR, a recent meta-analysis of 6 187 
RCTs of adults without diabetes showed a favourable effect of CPAP on IR vs. no CPAP (mean 188 
difference in HOMA-IR -0.43; 95%CI:-0.75 to -0.11, p=0.008)77.  189 
The impact of OSA on β-cell function is much less examined in the literature. In one study of patients 190 
without diabetes, patients with moderate-to-severe OSA had a lower β-cell function (measured using 191 
the disposition index during frequent sampling intravenous glucose tolerance test (IVGTT)) compared 192 
to healthy controls; and higher AHI was associated with lower β-cell function despite adjustment for 193 
obesity78. Similar results were found in a more recent study79 and in another study in patients with 194 
T2D80. Similar to IR, CPAP improved β-cell function in compliant patients with moderate to severe 195 
OSA without diabetes (uncontrolled trial)81 or with pre-diabetes (RCT)82. 196 
Mechanisms: OSA leading to dysglycaemia and T2D: 197 
There are several putative mechanisms linking intermittent hypoxia (IH) and sleep fragmentation to 198 
IR, β-cell dysfunction, and dysglycaemia33 summarised in Figure 3.  199 
In rodent models, IH has been shown to increase β-cell death 83 and impair β-cell function 84. Results 200 
from experimental studies in healthy adults showed that 5 hours of IH (24.3 events/h, average oxygen 201 
saturation 90.6%, range 75.4-98%) resulted in blunted, rather than increased, insulin secretion 202 
despite reductions in insulin sensitivity (based on  IVGTT)85. Chronic IH (CIH) can lead to β-cell 203 
dysfunction and IR via increased oxidative stress86, which pancreatic β-cells are less able to handle 204 
compared to other tissues87-89, and increased inflammation (increased CD8+ cytotoxic T-cells 205 
recruitment, shift to M1-proinflammatory macrophages in crown-like structures, IL and TNF-a)90, 91. In 206 
addition, chronic IH can increase free fatty acid (FFA) release leading to ectopic fat deposition in the 207 
liver and muscle rusting in IR90. The impacts of chronic IH and oxidative stress on IR could also be 208 
mediated by hypoxia-inducible factor (HIF) tissue effects92. In rodents, 35 days of chronic IH 209 
decreased insulin receptor expression and phosphorylation in skeletal muscle and adipose tissue, but 210 
not in the liver which was accompanied by up-regulation of HIF-1α in the liver and down-regulation 211 
HIF-1α and HIF-2α in skeletal muscle93. 212 
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Changes in sleep architecture can also contribute to the effects of OSA on glucose metabolism94. In an 213 
experimental study of young healthy adults, all-night suppression of SWS (without awakening the 214 
subjects, changing sleep duration, or REM sleep) was achieved via acoustic stimuli of varying intensity 215 
and frequency for three nights94. This resulted in a reduction in insulin sensitivity (by 25%, which is 216 
similar to a weight gain of 8-13 kg) without a compensatory increase in insulin release (based on 217 
IVGTT) 94. These changes in insulin sensitivity and β-cell function were associated with increased 218 
sympathetic activity and in some cases changes in cortisol levels94, 95. In addition, several other 219 
neurohormonal mechanisms are invovled in the links between OSA and T2D, which are summarised 220 
in Figure 3 30,39, 51, 65, 96-113. 221 
 222 
The impact of Dysglycaemia on OSA: 223 
While the impact of OSA on glucose metabolism has been widely studied, the impact of T2D and 224 
dysglycaemia on OSA has not received much attention. Many cross-sectional studies showed a high 225 
prevalence of OSA in patients with T2D as we detailed above, but whether this prevalence is higher 226 
than an age- and obesity- matched population without T2D remains unclear. Recently, a population- 227 
based study of 151,194 participants with T2D showed a Hazard risk of incident OSA 1.53 (95% CI: 228 
1.32-1.77) and further patients treated with insulin had higher risk of OSA, especially if they were 229 
women (1.43; 95%CI: 1.11-1.83)114. In addition, the incidence and natural history of OSA in patients 230 
with T2D are currently unknown. One longitudinal study assessed the relationship between IR and 231 
possible OSA prospectively and showed that HOMA-IR was an independent predictor for incident 232 
witnessed sleep apneas (not formally diagnosed OSA) over 6 years (OR: 1.31; 95%CI1.13-1.51)115.  233 
Several possible mechanisms make it plausible that dysglycaemia/diabetes can lead to the 234 
development or worsening of OSA as summarized in Figure 3 7, 11, 115-132.  235 
OSA in patients with T2D 236 
OSA and glycaemic control in T2D: 237 
Several cross-sectional studies in patients with T2D showed that patients with OSA had worse fasting 238 
plasma glucose, glycaemic variability and HbA1c compared to patients without OSA despite 239 
adjustment for confounders (difference in HbA1c between patients with and without OSA 0.7 to 240 
3.7%)7, 133-135. In addition, OSA severity is correlated with worse glycaemic measures7. Interestingly, 241 
one study showed that the relationship between AHI and HbA1c was only evident for the AHI during 242 
REM sleep and not during NREM sleep (after adjustment for confounders)136. This raised the 243 
possibility that OSA treatment might improve glycaemic parameters in patients with T2D.  244 
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Several uncontrolled trials showed that CPAP improved glycaemic variability, postprandial glucose 245 
levels and HbA1c over the short-term65, 137. However, 3 RCTs showed conflicting results. Two of these 246 
RCTs showed that CPAP had no impact on HbA1c138, 139, while another RCT showed that CPAP for 6 247 
months lowered HbA1c by −0.4% (95%CI: −0.7% to −0.04%; P = 0.029) while there was no change in 248 
HbA1c in the control group140. These conflicting results could be due to differences in studies 249 
population  (β-cell reserve), baseline glycemic control (for example one of the negative RCTs had a 250 
baseline HbA1c of 7.3%, while the RCT that showed positive effects of CPAP had baseline HbA1c of 251 
7.6%)139, or study duration (3 vs 6 months)138. There were no significant changes in weight or 252 
anthropometrics measures in these RCTs between the CPAP and the control arm to explain the 253 
conflicting results. However, an important difference between these RCTs was compliance with CPAP; 254 
the positive RCT showed CPAP usage of 5.2 hours per night compared to below 4 hours/night in the 255 
trial by West et al138, 140. Longer CPAP duration per night might have an important impact on 256 
glycaemic control as REM tend to occur later during sleep and the AHI during REM correlated with 257 
HbA1c better than the AHI during NREM82, 136. Hence, there is still a need for well-designed RCTs of 258 
longer CPAP duration to answer the question whether CPAP can (or cannot) improve glycaemic 259 
control in patients with T2D.   260 
OSA and vascular complications in patients with T2D: 261 
Several plausible mechanisms have led to the hypothesis that OSA could lead to the development or 262 
progression of macro- and micro- vascular complications in patients with T2D as shown in Figure 4 141-263 
146.  264 
The relationship between OSA and CVD in patients with T2D has not been studied widely. A 265 
retrospective observational study showed that in patients with T2D and newly diagnosed OSA, CPAP 266 
for 9-12 months lowered systolic (mean change -6.81, 95%CI -9.94 to -3.67) and diastolic (-3.69, -5.53 267 
to -1.85) BP 147. Similar reductions in BP levels were observed after 3 months of CPAP in an RCT in 268 
which patients with T2D and OSA were randomised to early (<1 week) or late (1–2 months) CPAP148. 269 
The Sleep AHEAD study showed an association between AHI and a history of stroke (adjusted OR 270 
2.57; 95% CI:1.03, 6.42) but not with coronary artery disease 149. In a longitudinal study in 132 271 
patients with T2D and a normal baseline exercise echocardiography test, OSA predicted incident 272 
coronary artery disease (adjusted HR 2.2; 95% CI: 1.2–3.9; p = 0.01) and heart failure (3.5; 1.4–273 
9.0; p < 0.01) over a median follow-up of 4.9 years150. In another recent study of 1311 patients who 274 
had percutaneous coronary intervention (PCI), OSA was associated with increased risk of major 275 
adverse cardiac and cerebrovascular events (MACCE) over 3 years in patients with diabetes mellitus 276 
(adjusted HR 2.03, 95% CI 1.10–3.74, P = 0.023) after adjustment for age, sex, ethnicity, BMI, and 277 
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hypertension151. There is no interventional RCT published regarding the impact of CPAP on CVD in 278 
patients with T2D. 279 
OSA has been shown to be associated with diabetes-related microvascular complications including 280 
peripheral neuropathy, chronic kidney disease (CKD), retinopathy and autonomic neuropathy71 . Most 281 
of these studies were cross-sectional and no interventional studies have been published although 282 
several are ongoing.   283 
A recent systematic review of 15 cross-sectional studies concluded that there was no convincing 284 
evidence that OSA was associated with diabetic retinopathy (DR), but that there was some evidence 285 
to suggest that OSA was associated with greater DR severity 152. The systematic review also suggested 286 
that OSA was associated with maculopathy152. It is plausible that the impact of OSA on DR is more 287 
related to disease progression rather than the development of disease (which is a function of 288 
hyperglycaemia) 7. The increased retinal oxygen demands overnight will make the retina particularly 289 
vulnerable to the effects of the IH that occur in patients with T2D and OSA. This is supported by a 290 
recent longitudinal study in patients with T2D in which OSA was not associated with the development 291 
of DR but was associated with progression to pre-proliferative and proliferative DR153. In this 292 
longitudinal study, OSA was associated with sight threatening DR (STDR) (adjusted OR 2.3; 95% CI, 293 
1.1–4.9; P = 0.035), and maculopathy (adjusted OR 2.7, 95%CI 1.2–5.9, p= 0.01) at baseline153. After a 294 
median follow-up of 43.0 (IQR 37.0-51.0) months, patients with OSA were more likely than patients 295 
without OSA to develop pre-proliferative/ proliferative DR (18.4% vs. 6.1%; P = 0.02), which remained 296 
significant after adjustment for potential confounders (adjusted OR 5.2; 95% CI 1.2-23.0; P = 0.03)153. 297 
Interestingly in this study, patients with moderate to severe OSA who were compliant with CPAP 298 
were significantly less likely to develop pre-proliferative/proliferative DR compared to non-compliant 299 
patients153. This finding was supported by another proof of concept study that showed that CPAP 300 
treatment ≥2.5 h/night CPAP over 6 months in individuals with OSA and significant macular oedema 301 
was associated with improvement in visual acuity but without improvement in the oedema 154. 302 
Currently, RCTs assessing the impact of CPAP on DR are ongoing. 303 
In a systematic review of 2 longitudinal and 10 cross-sectional studies there was an association 304 
between OSA and CKD in patients with T2D (pooled OR 1.73, 95% CI: 1.13-2.64)155. In a longitudinal 305 
study in patients with T2D, CKD prevalence was higher in patients with OSA vs. without OSA (49.3% 306 
vs. 23.8%, P < 0.001), which remained significant after adjustment for confounders (adjusted OR 2.64, 307 
95% CI 1.13-6.16), P = 0.02). OSA was also associated with lower eGFR and more micro- and macro- 308 
albuminuria156.  After an average follow-up of 2.5 (0.7) years, eGFR decline was greater in patients 309 
with vs. without OSA (median -6.8% [IQR -16.1 to 2.2] vs. -1.6% [-7.7 to 5.3%], P = 0.002)156. After 310 
adjustment, having OSA (B = -3.8, P = 0.044) and higher AHI (B = -4.6, P = 0.02) were predictors of 311 
lower study-end eGFR156.  312 
The relationship between OSA and peripheral neuropathy in patients with T2D was examined in a 313 
cross-sectional study, which showed that OSA is associated with peripheral neuropathy based on the 314 
Michigan Neuropathy Screening Instrument (MNSI) vs. patients without OSA (60% vs. 27%, P < 0.001), 315 
which remained significant after adjustment (OR 2.82; 95% CI 1.44-5.52; P = 0.003)143. In addition, 316 
OSA was associated with lower intra-epidermal nerve fibre density (based on skin biopsies), and a 317 
history of foot ulceration in patients withT2D141. These studies suggest that OSA was associated with 318 
both large and small fibre neuropathy in patients with T2D. Cohort studies and RCTs assessing the 319 
relationship between OSA and CPAP on diabetes-related neuropathy and its complications are 320 
ongoing. 321 
OSA and T1D: 322 
As patients with T1D tend to be lean or leaner than patients with T2D, examining OSA in T1D received 323 
much less attention than in T2D 157. However, there is increasing interest in OSA in patients with T1D, 324 
particularly that some recent studies suggest that OSA in T1D might be more related to autonomic 325 
neuropathy rather than obesity158. In addition, epidemiological studies suggest that obesity 326 
prevalence is increasing in patients with T1D which might further increase their risk of developing 327 
OSA  159. 328 
In a systematic review of 4 studies (n= 186 patients), the prevalence of OSA (defined as AHI≥ 5) was 329 
51.9% among adult patients with T1D, but the 95% CI was wide (31.2-72.6) reflecting the small 330 
sample size the variation between studies160. The prevalence of moderate to severe OSA (AHI ≥15) in 331 
the same meta-analysis was 16.7% (95% CI: 1.1, 34.5)160.  332 
Autonomic neuropathy was suggested as one potential mechanism for the high prevalence of OSA in 333 
T1D as shown in a cross-sectional study of 199 patients with T1D in which OSA was present in 32% of 334 
the patients with normal BMI 161.  And another study showed a higher prevalence of OSA in patients 335 
with T1D and cardiac autonomic neuropathy compared to patients with T1D but without neuropathy 336 
(67% vs. 23%)162. Other factors might contribute to the high prevalence of OSA in children and 337 
adolescents with T1D including lower mean lung volumes (FVC, PEF, MMEF) 163, 164 and impaired gas 338 
exchange with lower diffusing capacity for carbon monoxide 165. There are similar findings of impaired 339 
pulmonary function in adult patients with T1D166-168. The natural history, impact, and pathogenesis of 340 
OSA in patients with T1D remain poorly explored and large well-designed studies are needed. 341 
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OSA & the Renin-Angiotensin-Aldosterone System (RAAS) 342 
The links between OSA and RAAS activation are potentially bi-directional (Figure 5). 343 
Hyperaldosteronism might also play an important role in the well-established links between OSA and 344 
hypertension (particularly resistant hypertension-RH) (Figure 5)9, 169-173.  345 
The pathophysiology of hyperaldosteronism in patients with OSA is mainly attributed to the 346 
activation of the RAAS due to cyclical/intermittent hypoxia172. In addition, some studies suggested a 347 
higher prevalence of primary aldosteronism (PA) in patients with OSA compared to patients without 348 
OSA173. 349 
A recent meta-analysis has examined the relationship between OSA and RAAS activation174 . The 350 
meta-analysis included 14 studies, all but one, were case-control studies and they included a 351 
relatively small sample size (mostly < 100, range 12 to 120) 174. The studies generally included middle 352 
age men and 8 of them included patients with hypertension174. The meta-analysis found no significant 353 
relationship between OSA and plasma renin activity (PRA) (mean difference 0.17 ng/mL per hour 354 
(95% CI: -0.22 to 0.55, P = 0.40)) or plasma renin concentration (PRC) (mean difference 0.95 ng/mL 355 
(95% CI: –0.58 to 2.48, P = 0.23)174. However, angiotensin II levels were significantly higher in patients 356 
with OSA compared to those without OSA (mean difference of 3.39 ng/L; 95% CI 2.00 to 4.79, P < 357 
0.00001)174. There was a trend towards higher plasma aldosterone concentration (PAC) in patients 358 
with OSA vs. no OSA (mean difference 0.95 ng/dL; 95% CI: –0.16 to 2.07, P = 0.09)174. However, when 359 
examined in patients with and without hypertension separately, patients with hypertension and OSA 360 
had significantly higher PAC vs. patients with hypertension but without OSA (mean difference 1.32 361 
ng/dL; 95% CI: 0.58 to 2.07, P = 0.0005)174. 362 
The above-mentioned meta-analyses had high heterogeneity, which could be due to variations in the 363 
definition of OSA174. The heterogeneity can also be attributed to the medication used prior to RAAS 364 
measurements; however, a meta-regression showed that anti-hypertensives did not affect the 365 
relationship between OSA and PAC174. Supporting the findings of this meta-analysis, another study 366 
showing that the AHI correlated significantly with PAC and urinary aldosterone levels (r= 0.568, p = 367 
0.0009; r = 0.533, p = 0.002, respectively) in patients with RH and hyperaldosteronism175. 368 
Several uncontrolled studies in patients with hypertension (mostly RH) showed that CPAP lowered 369 
angiotensin II and aldosterone levels176-179. One RCT in which 117 patients with RH were 370 
randomised to CPAP (n=57) vs. no CPAP (n=60) showed that 6 months of CPAP resulted in greater 371 
reduction in aldosterone excretion (based on 24 h urine) compared to the control group in the per-372 
protocol analysis (mean difference: -3.3 μg/24 h; 95% CI -6.1 to -0.4 μg/24 h; P = 0.027)180. 373 
However, the intention to treat analysis showed only a trend (p=0.07). The impact of CPAP on 374 
lowering aldosterone was particularly evident in those with uncontrolled hypertension, non-375 
dipping in nocturnal BP, not using spironolactone, and with patients with worse hypoxia180. A 376 
recent meta-analysis of 3 observational studies and 2 RCTs (did not include the above-mentioned 377 
RCT) showed that CPAP lowered aldosterone levels compared to no/sham CPAP (mean difference -378 
0.236, 95 % CI -0.45 to -0.02, p = 0.034)181.  379 
Chronic IH seems to play an important role in the impact of OSA on the RAAS and the mechanistic 380 
pathway is shown in Figure 5 172,182-185,176-178. 381 
On the other hand, RAAS activation and hyperaldosteronism might lead to or worsen OSA via 382 
multiple mechanisms as detailed in Figure 5. In a retrospective cohort registry based study, the 383 
risk of developing OSA was higher in patients with hypertension and hyperaldosteronism 384 
compared to those without hyperaldosteronism after adjustment for age, sex, BMI, diabetes 385 
mellitus, and heart failure (adjusted OR: 1.8; 95% CI 1.3-2.6)186.  Moreover, in a cross-sectional 386 
study of patients with RH, spironolactone treatment was associated with lower AHI187. In another 387 
uncontrolled study in patients with RH, spironolactone (25-50mg daily for 8 weeks) improved OSA 388 
severity (based on PSG) ( AHI: 39.8±19.5 vs 22.0±6.8 events/h; P<0.05;) 188. A  recent systematic 389 
review and meta-analysis found 3 studies (1 RCT) and concluded that spironolactone reduced the 390 
AHI by a mean of −21.12 (95% CI −27.47 to −14.77, P<0.00001)175.  Furthermore, in a small study of 391 
20 patients with PA who had PSGs, having  MR antagonists (n=13) or adrenalectomy (n=7) resulted 392 
in AHI reduction from 22.5 (14.7) to 12.3 (12.1) (P=0.02)185. These studies support the notion that 393 
hyperaldosteronism could worsen OSA and suggest that aldosterone antagonists can be useful in 394 
patients with hypertension or PA and OSA. 395 
Finally, due to the links between OSA and PA the recent guidelines of the Endocrine Society on the 396 
management of PA recommend that patients with hypertension and OSA are screened for PA173. 397 
Furthermore, well designed RCTs assessing the impact of MR antagonists on OSA are needed, 398 
particularly that OSA is associated with increased CVD risk and that CPAP compliance is often not 399 
optimal. 400 
Although not directly related to RAS activation, it is important to note that patients with OSA can 401 
present with hypertension and the clinical and biochemical features of phaeochromocytoma without 402 
the presence of a catecholamine secreting tumour (i.e. pseudo-phaeochromocytoma)110, 189-191. These 403 
cases are rare but have been reported in multiple case reports and series, and the clinical and 404 
biochemical features usually resolve with CPAP treatment or weight loss110, 189-191. 405 
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OSA & hypothalamic-pituitary-adrenal (HPA) axis 406 
Cortisol secretion has a well described circadian rhythm and is closely related to sleep stages192, 193. 407 
Sleep onset and SWS are associated with a decline in cortisol levels followed by increased cortisol 408 
secretion in late sleep (which is consistent with the rise in early morning)194. On the other hand, 409 
cortisol might impact on sleep architecture, for example, HPA axis hyperactivity inhibits SWS and 410 
promotes nocturnal awakening193.   411 
OSA and HPA axis activation: 412 
The impact of OSA on HPA axis is controversial with conflicting results due to the confounding effects 413 
of obesity, the sampling frequency (single time point vs. 24-hours profile), variability in matching 414 
between patients with and without OSA, small sample sizes, and short CPAP duration with variability 415 
in compliance. Some studies showed no relationship between OSA and the HPA axis, while some even 416 
suggested that OSA might inhibit the HPA axis [AHI and ODI correlated negatively with morning 417 
cortisol levels: r = −0.444, P = 0.002 and r = −0.381, P = 0.011 respectively) 195-198. In a systematic 418 
review of studies that compared cortisol levels in patients with OSA to either obese or lean control, 419 
there was no evidence of HPA activation in patients with OSA in 6/7 studies199. However, only 2 of 420 
these studies had plasma cortisol measurements over 24-h, while the rest had single time point 421 
measurements199. The two studies that measured 24-h cortisol profile reported contradicting results 422 
as one showed no difference in mean 24-h plasma cortisol between patients with OSA and obese 423 
controls200, while the other showed that OSA was associated with HPA activation compared to obese 424 
controls 201.  425 
However, the impact of OSA on HPA axis may not necessarily be consistent over the 24-h period, as 426 
the study by Vgontzas et al. showed that mean plasma cortisol levels between 23:00h and 7:00h were 427 
higher in patients with OSA and obesity vs. obese controls, consistent with nocturnal HPA activation 428 
when there is intermittent hypoxia and disruption of the sleep architecture201(Figure 6). Another 429 
important aspect is that the impact of OSA on HPA axis may not be simply related to basal or 24-h 430 
cortisol profiles but might be related to the dynamic responses to HPA inhibition or stimulation. 431 
Carneiro et al. showed that although basal salivary cortisol wasn’t different between patients with 432 
OSA vs. obese controls, the salivary cortisol inhibition following overnight dexamethasone 433 
suppression test (ONDST) was significantly less pronounced in patients with OSA compared to obese 434 
controls196. Interestingly, this deficit was corrected after 3 months of CPAP196. Another study also 435 
showed that ACTH responses to CRH stimulation were higher in patients with OSA compared to obese 436 
and lean controls202. 437 
  438 
In the same above-mentioned systematic review, 8 uncontrolled studies assessed the impact of CPAP 439 
on cortisol levels (blood or salivary)199. Five studies showed no impact76, 196, 203-205, while 3 studies 440 
showed that CPAP lowered cortisol levels (blood and salivary)201, 206, 207.  The studies that showed 441 
favourable impacts of CPA measured cortisol more frequently during the 24 hours compared to the 442 
negative studies199. However, a recent in-laboratory study showed that 8 hours of CPAP per night did 443 
not have any effect on 24-h cortisol profile208.  Nonetheless, this study was over a 1-week period, 444 
unlike the studies that showed positive impact of CPAP on cortisol which were over 3 months period.  445 
A slightly longer study of 14 days, showed that CPAP can lower morning salivary cortisol in men and 446 
women with obesity and OSA209. The confounding effects of obesity and gender on the relationship 447 
between OSA and HPA axis were addressed in a recent study of non-obese men and postmenopausal 448 
women which showed that OSA patients had higher 24h blood cortisol levels compared to controls, 449 
which were lowered after 2 months of CPAP51. 450 
Overall, while the studies showed conflicting results there is evidence that OSA is associated with HPA 451 
activation particularly nocturnally and that CPAP (14 days to 3 months) can lower cortisol 24-h profile 452 
rather than cortisol levels at single time points. The effects of OSA on the HPA axis can be mediated 453 
via mechanisms related to night awakenings (even when brief), sleep restriction, and intermittent 454 
hypoxia51, 210-216 as shown in Figure 6.    455 
OSA in patients with Cushing’s syndrome: 456 
Several studies have shown that OSA is common in patients with Cushing’s syndrome (CS) (whether 457 
endogenous or exogenous)217. The prevalence of OSA (based on PSG) was higher in women with 458 
active CS (n=35) compared to age- gender- and BMI- matched controls (n=30) (50% vs 459 
23%, P = 0.003)218. After controlling for BMI and HOMA score, serum cortisol remained independently 460 
associated with AHI (R2: 77.8%, P < 0.001), suggesting that the relationship between CS and OSA are 461 
not only related to obesity218. A recent Taiwanese population-based cohort study showed that 462 
patients with CS (n=53) were at increased risk of developing OSA compared to matched controlled 463 
(matched for age, sex and comorbidities including obesity, T2D, and hypertension)  ( 4.11 vs. 1.70 per 464 
thousand person/ year; HR 2.82, 95% CI: 1.67-4.77), with slightly higher risk in men vs. women219. 465 
Interestingly in this study, the survival curves for OSA development starting separating clearly from 466 
the first year after the diagnosis of CS219. Similarly, in patients without OSA (n=17) who had PSG 467 
before and after 3 months of prednisolone (10mg daily or more), AHI worsened by 56% compared to 468 
controls (with mild OSA but no steroid treatment)220. This increase in AHI did not correlate with 469 
changes in weight and neck circumference suggesting mechanisms other than adiposity responsible 470 
for the worsening in AHI220.  471 
 472 
While obesity might play an important role in the relationship between CS and OSA, it is clear from 473 
the above-mentioned studies that obesity is not the only factor. In addition to obesity, 474 
hyperglycaemia, IR, and ectopic fat (in the peritoneum, mediastinum and parapharyngeal spaces) 475 
may also play a role in the increased risk of OSA in patients with CS217, 221. Moreover, hypercortisolism 476 
can induce UA myopathy leading to compromised UAs (Figure 6)217, 219, 222. 477 
Future studies need to assess the impact of CS treatment on the incidence and severity of OSA and to 478 
examine whether the increased OSA risk in patients with CS is lifelong or simply related to the period 479 
where CS is active. In addition, endocrinologists, surgeons and anesthetists need to be aware of the 480 
high risk of OSA in patients with CS when considering surgical treatment (both pituitary and adrenal) 481 
in order to ensure the safety of the surgical intervention.  482 
OSA & Growth Hormone (GH)/IGF axis 483 
Summary of OSA impact on GH/IGF axis as well as the relation of GH excess and deficiency to OSA 484 
development or worsening can be found in Figure 7.  485 
 486 
OSA and the dysregulation of GH/IGF axis 487 
OSA-associated chronic IH and disruption of sleep architecture can lead to dysregulation of the 488 
GH/IGF axis as GH secretion is increased after sleep onset and during SWS (both of which are 489 
disrupted in patients with OSA)223, 224. Overall, studies in rodents and humans suggest that OSA is 490 
associated with suppression of basal and stimulated GH and IGF-1 levels which are improved by 491 
CPAP225. 492 
In rodents,  IH was shown to cause a recoverable dose-dependent suppression of GH release and GH 493 
mRNA expression, possibly due to modulation of somatostatin activity226. In humans, OSA was shown 494 
to be associated with a marked reduction in GH blood levels, which increased following one night of 495 
CPAP64. In addition, fasting IGF-1 levels correlated negatively with the ODI in men with OSA, but 496 
increased following 3 months of   CPAP195. Sleep disruption also plays a role in the relationship 497 
between OSA and the GH/IGF-1 axis. In an experimental study of patients with OSA who were 498 
examined for 1 night without CPAP and 1 night with CPAP, GH plasma levels and secretion rate 499 
(bloods were collected every 10 minutes over night) were reduced and increased after CPAP 500 
treatment; this improvement correlated with the improvement in SWS227. 501 
In support of the impact of OSA on the GH/IGF axis, a recent RCT in 65 middle-aged men with 502 
moderate to severe OSA showed that CPAP vs sham CPAP increased IGF-1 levels, total and pulsatile 503 
GH secretion, mean GH concentration, mass of GH secreted per pulse and pulse frequency after 12 504 
weeks of treatment with further increases in IGF-1 levels and a decrease in IGFBP-1 levels by week 505 
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24228. Furthermore, other treatments that can improve OSA, such as adenotonsilectomy in children, 506 
have also been shown to improve IGF-1 and IGFBP-3 levels229.  507 
Obesity is a potential confounder for the relationship between OSA and GH/IGF-1 dysregulation as 508 
obesity (particularly visceral) is linked to a reduction in GH secretion, IGF-1 levels and peripheral GH 509 
sensitivity, which can recover with weight loss230. However, IGF-1 levels were lower in patients with 510 
OSA compared to the weight matched controlled despite that both these groups had lower IGF-1 511 
levels compared to the lean control96.  512 
OSA and acromegaly 513 
Many cross-sectional studies showed that OSA is highly prevalent in patients with active acromegaly 514 
(45-80%)231, with an average prevalence of 69% in PSG-based studies 232. Although lowering GH/IGF-1 515 
improves OSA, up to 40% ( range 21-58%231) of those with controlled acromegaly have persistent OSA 516 
that required evaluation and the consideration of CPAP233, 234. “Although clinicians seem to be aware 517 
of the links between acromegaly and OSA (as shown by a survey in Italy), only few patients undergo 518 
PSG in clinical practice235. 519 
In addition, OSA contributed to the adverse outcomes of acromegaly, despite that there were no 520 
differences in GH or IGF-1 levels between patients with OSA + acromegaly vs. acromegaly alone236. 521 
The presence of impaired glucose tolerance or T2D was higher in patients with acromegaly and OSA 522 
vs. acromegaly only (n: 10/17 vs. 5/19)236; although this was not adjusted for obesity. In addition, OSA 523 
contributed to insulin resistance in patients with acromegaly, which improved by CPAP in a RCT237. 524 
Furthermore, OSA might play an important role in other acromegaly-related comorbidities such as 525 
hypertension and heart failure/cardiomyopathy238.  526 
As a result of the high prevalence of OSA and its impact on acromegaly-related comorbidities, the 527 
2014 Endocrine Society Clinical Practice Guideline for acromegaly recommended evaluating all 528 
patients for OSA234. In addition, the guidelines recommended that patients with severe pharyngeal 529 
thickness and OSA should be treated with somatostatin receptor ligands preoperatively to reduce the 530 
OSA-related surgical risks234.  531 
 532 
On the other hand, a recent study of 507 patients with OSA showed that 10 patients (1.97%) had 533 
elevated IGF-1 levels, of which 9 patients suppressed GH levels on OGTT giving an acromegaly 534 
prevalence of 0.2% (1/507)239. These findings suggest that screening for acromegaly in OSA should not 535 
be routinely performed. However, if in addition to OSA, there are other features of acromegaly or 536 
acromegaly-associated conditions (such as T2D, debilitating arthritis, carpal tunnel syndrome, 537 
hyperhidrosis, and hypertension), then measurement of IGF-1 levels is recommended as per the 538 
Endocrine Society Clinical Practice Guideline for acromegaly239. Finally, although we have focused 539 
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here on OSA, central sleep apnoea (SA) can also occur in the context of acromegaly240, but far less 540 
common than OSA236. 541 
 542 
The mechanisms leading to the high prevalence of OSA in patients with acromegaly are summarised 543 
in Figure 7 231, 234, 240-254 .  544 
The impact of Acromegaly treatment on OSA: 545 
Considering that OSA is driven by the excess of GH/IGF-1 in patients with acromegaly, it is not 546 
surprising that treating acromegaly can improve OSA but it is also common for OSA to persist or even 547 
worsen after acromegaly is brought under control234. In a small study of 6 patients with SA syndrome 548 
(obstructive or central with EDS) and acromegaly, trans-sphenoidal adenomectomy resulted in 549 
resolution of the SA syndrome in all patients regardless of whether acromegaly was cured or not255. In 550 
another study of 24 patients with acromegaly (20 with OSA)  who had remission following trans-551 
sphenoidal surgery; at 1 month post-surgery, the tongue area declined while the airway volume 552 
increased significantly, accompanied with improved OSA256. The prevalence of severe OSA was 553 
reduced from 45.8% to 28% by 6 months with significant improvements in AHI but the average AHI 554 
remained in the moderate OSA range 256. Similar results were observed in patients with acromegaly 555 
following treatment with somatostatin analogues 246, 249, 257-260 and pegvisomant 261, 262.  556 
The above-mentioned studies clearly show that curing acromegaly or significant improvements in 557 
GH/IGF-1 levels can improve OSA, but many patients with acromegaly have persistent moderate to 558 
severe OSA that might require CPAP. In fact, OSA might occur in patients with acromegaly following 559 
achieving normal IGF-1 levels even when OSA was not present at baseline as shown by Chemla et al 560 
(OSA cured in 57%, new OSA that was not present at baseline 22%)263. Similarly, Castellani et al. 561 
showed that AHI  increased in 55.5% of patients with acromegaly after complete/ partial biochemical 562 
control (either after surgery, radiotherapy, and/or medical therapy)231. OSA persistence following 563 
acromegaly treatment is probably due to multiple factors including increased BMI and/ or irreversible 564 
craniofacial-skeletal deformities/fibrosis231. Hence, OSA evaluation is needed post acromegaly 565 
treatment regardless of the normalisation of GH/IGF-1 264. 566 
 567 
OSA in adults with GH deficiency (GHD): 568 
OSA is much less examined in GHD in comparison to acromegaly. OSA is very common in adults with 569 
GHD  with a prevalence of 63%; which is mainly due to the increased obesity either due to GHD or 570 
hypothalamic obesity as a result of surgical or radiotherapy treatment delivered to the underlying 571 
pituitary or hypothalamic pathology 265. 572 
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GH replacement and OSA: 573 
GH replacement in patients with GHD might improve OSA due to a reduction in adiposity (strong 574 
lipolytic properties of GH266, 267) or it could worsen OSA if the replacement was excessive. The studies 575 
in the literature show a mixed picture. In a small study of 5 men who received GH replacement 576 
(median dose 2 U/day; median serum IGF-I 351 mcg/l) for 1-2 years post pituitary surgery GHD, 577 
showed that 6 months after stopping GH treatment the median obstructive AHI decreased 578 
significantly from 4.4 to 0.1 (P = 0.03) whereas the central AHI increased from 6.3 to 14.6 (P = 0.03); 579 
suggesting that GH replacement worsened the OSA but improved central SA 268. However, another 580 
study of 19 patients with GHD showed that GH replacement for 6 months had no impact on AHI (pre 581 
vs post treatment: 28.2/h vs. 28/h), regardless of baseline OSA status265. Still, in a large observational 582 
longitudinal study of GH-treated (n = 1988) and untreated (n = 442) patients with GHD showed that 583 
after a mean follow up of 2.3 years the sleep apnoea incidence was greater in the group that received 584 
GH replacement (3.3% vs 0.9%, p<0.05), despite that the GH treated vs. untreated groups had similar 585 
BMI at baseline and the GH-treated group were younger 269.However, the GH-treated group had 586 
higher baseline IGF-1 levels (108 ± 61 vs. 90 ± 51 mcg/l, p <0.001) and serum IGFBP-3 levels (2.4 ± 0.9 587 
vs. 2.1 ± 1.0 mcg/l, p<.001)269. In a 12-month double blind RCT of 40 men with obesity and 588 
dysglycaemia who were randomised to either GH or placebo; GH treatment increased IGF-1 from 589 
168±72 to 292±117 mcg/L, the AHI from 31±20 to 43±25 and the ODI from 18±14 to 29±21 (all p 590 
values ≤ 0.001)270. Interestingly, GH treatment in this study increased neck transverse diameter, 591 
circumference, and total cross-sectional area, while reduced abdominal visceral adipose tissue (based 592 
on CT)270. 593 
 594 
Hence, more data is required to assess the impact of GH replacement on pre-existing OSA and the 595 
development of new OSA. However, GH replacement might result in the development or worsening 596 
of pre-existing OSA via increasing IGF-1 levels or via affecting adipose tissue distribution (increasing 597 
neck circumference). 598 
 599 
OSA in Prader -Willi syndrome 600 
Children and patients with Prader-Willi syndrome (PWS) are also at high risk of having OSA 601 
(prevalence: 1:10,000- 25,000 live children), and as a result screening for OSA in this population has 602 
been recommended 271. The high prevalence of OSA in patients with PWS is likely to be multifactorial 603 
due to GH deficiency, increased viscosity of upper airways secretions, craniofacial abnormalities with 604 
small airways, upper airways muscles hypotonia and secondary alveolar hypoventilation (obesity and 605 
scoliosis causing lung volume restriction) all leading to airway collapsibility 271.  606 
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The impact of GH replacement on OSA in children with PWS is debatable. Salvatoni et al. showed that 607 
short-term treatment with rhGH (6 weeks) did not worsen the AHI and there was no difference in 608 
AHI between the treatment and control group at baseline or study-end272. Nonetheless, in this 609 
study, the AHI increased (i.e. OSA worsened) in 50% of the cases following GH replacement272. 610 
Similar results were shown in another study suggesting that the AHI worsen in a subgroup of 611 
patients following GH replacement over the short run273; which in part could be due to the 612 
development of adenotonsillar hyperthophy following GH treatment273. However, longer term follow-613 
up (2 years) showed that GH replacement did not worsen AHI during the follow up except in those 614 
who worsened shortly after GH initiation 274, 275. As a result, the 2013 consensus guidelines considered 615 
untreated severe obstructive sleep apnea as an exclusion criteria for rhGH initiation, till the patient is 616 
treated with CPAP276, 277. This is particularly important considering that sudden death early in the 617 
course of GH replacement in patients with PWS, associated with sleep disordered breathing/OSA, 618 
have been reported in the literature278-280. 619 
 620 
OSA & hypothalamic-pituitary-thyroid (HPT) axis  621 
OSA in patients with hypothyroidism 622 
A recent systematic review of 1 observational and 5 interventional studies (501 patients in their 4th-623 
5th decade of life) found that 25-50% of patients with overt hypothyroidism (OH) had nocturnal 624 
breathing abnormalities (snoring, choking, apnoea periods); which improved with levothyroxine 4 625 
(LT4) treatment281. In one study, 30% of patients with recently diagnosed OH had evidence of OSA 626 
(AHI ≥ 5 based on PSG), and LT4 improved the AHI (from a median of 14.3 (7.4–33.6)  to 2.1 (0.8–627 
4.6))282 . In addition, in the later study LT4 treatment improved hypoxaemia and sleep architecture 628 
(TpO2 sat<90%c:  14% (2.2–19.9) vs 0.2% (0–1.7), p<0.05;  SWS%:  18.4 (7.2–25.2) vs 28.2 (15–33.4), 629 
p<0.05)282. This suggests that hypothyroidism can lead to/worsen OSA which improves with LT4 630 
treatment. However, larger studies including RCTs are needed before confirming this relationship. 631 
There is lack of good quality data regarding the relationship between OSA and subclinical 632 
hypothyroidism (SH); one small observational study (n=108) showed that 53% of patients with 633 
untreated SH had OSA (based on PSG)283. However, these results are likely to represent selection bias 634 
as the prevalence of OSA in healthy controls with normal thyroid functions was higher (75%) than 635 
that in patients with untreated SH despite that SH patients were heavier and the patients recruited 636 
from the respiratory department 283. Hence, currently we cannot be certain about the relationship 637 
between OSA and SH.  638 
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Hypothyroidism in patients with OSA 639 
While studies are not consistent, overall there is no evidence that hypothyroidism is more common in 640 
patients with OSA compared to patients without OSA284, 285. A recent study also supported this 641 
conclusion as it showed that the prevalence of raised TSH in 813 patients with severe OSA was 4.7% 642 
which is similar to the general population286. Some studies showed that the prevalence of SH was 643 
higher in OSA vs. control, but these studies have potential selection bias as the population was 644 
recruited from sleep clinics and the control group was younger and leaner287-289. Other studies did 645 
not show a high prevalence of SH in patients with OSA290.  In a study of 245 euthyroid patients with 646 
suspected OSA, the prevalence of Hashimoto’s thyroiditis was 32.2% in patients without OSA vs. 647 
46.8% in patients with OSA (based on PSG) (p=0.03) 291. The prevalence of Hashimoto’s increased with 648 
worsening severity of OSA291. 649 
Mechanisms linking OSA and thyroid disorders:  650 
Hypothyroidism can lead to the development or worsening of OSA via multiple mechanisms 651 
summarized in Figure 8 232, 281, 282, 284, 291-300.   652 
OSA and non-thyroidal illness syndrome (NTIS) 653 
A recent cross-sectional study showed that patients with moderate to severe OSA (n=125) had a 654 
higher prevalence of NTIS (defined as normal TSH and low FT3) compared to controls (n=60) (10.4% 655 
vs. 0%), but the control group was lean and there were more men in the OSA group301. Within the 656 
OSA group, patients with NTIS had worse nocturnal hypoxemia compared to patients without NTIS 301. 657 
This suggests that IH could play a role in the high prevalence of NTIS  in patients with OSA, possibly 658 
via down-regulation of deidodinase 1 and enhancing deiodinase 3 inactivating T3 and T4302. In 659 
addition, oxidative stress and low grade inflammation, resulting from OSA, can also contribute to the 660 
association between OSA and NTIS303, 304. CPAP for 5 months has been shown to improve FT3 levels in 661 
patients with NTIS supporting the notion that OSA might lead to NTIS, but this study was not 662 
controlled 301. However, it is important the clinicians take into account the possibility of NTIS when 663 
interpreting thyroid function results in patients with OSA.   664 
In summary, sleep apnoea and thyroid specialists need to have a low threshold to test for thyroid 665 
disorders if indicated clinically. In addition, OSA can be associated with NTIS and clinicians 666 
interpreting the thyroid function results need to take the presence of OSA into consideration. 667 
However, cohort studies with well-matched control groups and RCTs are needed to enable us to 668 
understand the complex relationship between OSA and HPT axis and the impact of treating one or the 669 
other.  670 
OSA & the Hypothalamic-Pituitary-Gonadal (HPG) axis 671 
The interaction between sex hormones and OSA was initially brought to attention by the consistently 672 
reported a higher prevalence of OSA in men vs. women. This relationship was further emphasized by 673 
several observations including that testosterone replacement in men worsens/ increases the risk of 674 
having OSA, the prevalence of OSA in postmenopausal women was higher than in premenopausal 675 
women; hormone-replacement therapy reduced the risk of OSA in postmenopausal women and oral 676 
contraceptives were associated with lowered OSA risk in women with polycystic ovarian syndrome 677 
(PCOS)65, 305. 678 
In Men 679 
OSA is associated with hypogonadotropic hypogonadism due to altered gonadotropin synthesis and 680 
release306. In a cross-sectional analysis of a prospective study of healthy older men (n=1312, ≥65years 681 
old), lower testosterone levels (based on quartiles) were associated with significantly less SWS, higher 682 
AHI (based on PSG) and more sleep time spent with O2 sat<90% after adjustment for age and race307. 683 
However, adjustment for BMI made these associations non-significant307. Other studies showed that 684 
patients with OSA had lower area under the curve and mean levels for LH (24.9 ±  10.2 IU/l h vs. 43.4 685 
±  9.5 IU/l, P < 0.005) and testosterone (67.2 ± 11.5 nmol/l vs. 113.3 ± 26.8 nmol/l, p=0.003) 686 
compared to healthy controls, but the control group was leaner numerically 308. Similar findings were 687 
found in other studies 309-311. 688 
Testosterone replacement and OSA 689 
Patients receiving testosterone replacement are at increased risk of developing OSA. In a cohort 690 
study, 3422 of US military service members, aged 40-64 years, who were free of OSA at baseline and 691 
received testosterone replacement, were matched based on age and comorbidities to men who did 692 
not receive testosterone treatment312. The absolute 2-year risk of incident OSA was greater in 693 
patients that received testosterone replacement vs those who did not (16.5% (95% CI: 15.1–18.1) vs 694 
12.7% (95% CI: 11.4–14.2), p<0.001)312. Interestingly, the increased risk of OSA was greater for those 695 
who used injectable vs topical testosterone312. This is also supported by a small RCT in which healthy 696 
ambulatory men aged > 60 years were randomised to receive three injections of weekly 697 
intramuscular testosterone esters (500 mg, 250 mg, and 250 mg) or matching oil-based placebo and 698 
then crossed over to the other treatment after 8-week washout. Testosterone replacement in this 699 
RCT resulted in worsening RDI (approximately by 7 events per hour), mainly during non-rapid eye 700 
movement  (NREM) sleep, and worsened nocturnal hyoxaemia measures; while placebo had minimal 701 
effects on RDI and hypoxia parameters 313. Several other studies suggested a link between 702 
testosterone replacement and incident or worsening OSA314-317. As a result, the Endocrine Society 703 
clinical practice guidelines recommended against the use of testosterone replacement in men with 704 
untreated severe OSA318. It is unclear whether different methods of testosterone replacement have a 705 
differential impact on the risk of developing or worsening OSA due to the variations in the 706 
pharmacokinetics profiles of these agents. 707 
The effects of testosterone can be time-limited as shown in a RCT of 67 men who received 708 
hypocaloric diet and were randomised to intramuscular injections of 1000 mg testosterone 709 
undecanoate or placebo 319, in which testosterone replacement worsened the ODI by 10.3 events/h 710 
(95%CI, 0·8–19·8 events/h; P = 0·03) and on nocturnal hypoxaemia at 7 weeks but not at 18 weeks319. 711 
This time dependent effects might be as a result of time dependent changes in hyperoxic ventilatory 712 
recruitment threshold following testosterone replacement320.   713 
Mechanisms 714 
Low testosterone in men can lead to loss of muscle mass and increased visceral adiposity, which can 715 
contribute to the increased/worsening OSA in men with hypogonadism321, 322. It is unclear how 716 
testosterone replacement leads to OSA, but postulated mechanisms include altered ventilator 717 
responses such as increased response to hypoxaemia (leading to CO2 levels below apnea threshold), 718 
reduced sensitivity to hypercapnia, or anabolic effects (leading to UA narrowing) and an effect on the 719 
neuromuscular control of UA323, 324. However, these mechanisms are not well proven with multiple 720 
studies showing conflicting results. In one interesting mechanistic study, androgen blockade with 721 
flutamide did not influence chemo-responsiveness to hypoxia/ hypercapnia325.   722 
In addition, OSA can impact the HPG axis via several mechanisms including IH, sleep fragmentation 723 
and obesity306, 310, 326. Testosterone levels peak during REM (fewer REM sleep episodes and REM sleep 724 
latency are related to lower testosterone concentrations323), hence the disruption of sleep 725 
architecture in OSA (loss of REM) might explain the link between OSA and low testosterone193.   726 
The impact of OSA treatment on the HPG axis: 727 
CPAP effects on the HPG axis in men remains controversial with a limited number of studies in the 728 
literature. A meta-analysis in 2014 found only 2 RCTs and 5 observational studies with a total sample 729 
size of 232 men showing the paucity of available data327. In this meta-analysis, an average of 6 730 
months of CPAP treatment had no effects on testosterone levels despite good CPAP compliance 731 
(standardized mean difference (SMD) = -0.14, 95%CI: -0.63 to 0.34)327. CPAP also had no effects on 732 
free testosterone or SHBG levels327.  733 
 734 
Summary of the trials assessing the impact of OSA treatment (CPAP and surgical) on HPG axis can be 735 
found in Table 1 (195, 205, 328-335). The 2 RCTs showed no effect of CPAP on testosterone levels, but the 736 
study participants did not have hypogonadism at baseline and the CPAP duration was short. The 737 
uncontrolled studies mostly showed no effects of CPAP on testosterone levels except 2 studies, that 738 
showed that CPAP increased testosterone levels (Table 1). In one of these studies, the increase in 739 
total testosterone was associated with increased SHBG which suggest that the impact of free 740 
testosterone was rather limited. In the other study, patients had hypogonadism at baseline and CPAP 741 
improved testosterone levels along with LH, but the impact on SHBG was not reported (Table 1). 742 
Hence, the impact of CPAP on HPG axis in men remains unclear but future trials need to consider the 743 
potential difference in response between men with and without hypogonadism and need to ensure 744 
adequate CPAP treatment duration and the impact on free testosterone. 745 
It is Important to note that CPAP might still have beneficial impacts on scores for sexual and erection 746 
function despite the lack of impact of hormonal measurements332, 333. However, in two RCTs sildenafil 747 
was superior to CPAP in regards to ED336, 337. 748 
 749 
In women 750 
OSA impact on the HPG axis in women is less well studied compared to men. Based on animal studies 751 
sex hormones can influence breathing not only via androgens but also via the effects of progesterone 752 
and estradiol on CB and the brainstem338. In addition, lack of progesterone receptor in rodent led to 753 
reduced hypoxic ventilator response339 and lower UA resistance was found in the luteal phase in 754 
healthy premenopausal women with the peak in progesterone secretion340. On the other hand, OSA 755 
has a negative effect on female sex hormones and on sexual function and is associated with PCOs. 756 
In a cohort of 53 women (24-72 years old), AHI>10/hr was associated with lower morning levels of 17-757 
OH-progesterone, progesterone and estradiol341. However, hormone replacement therapy (HRT) in 758 
post-menopausal women was associated with lower prevalence of moderate to severe OSA 759 
prevalence compared to women not taking HRT and less time spent in oxygen saturations < 90%, 760 
particularly in women who received combined estrogen-progesterone vs. estrogen alone 342. The 761 
impact of CPAP on the HPG axis in women remains to be explored in large studies, and since one 762 
small uncontrolled study showed no effect330 RCTs in this area are needed. 763 
Similar to men, OSA has been associated with sexual dysfunction (FSFI score: desire, arousal, 764 
lubrication, orgasm, satisfaction, and pain) in pre- and post- menopausal women compared to 765 
matched controls 343, 344 345. Unlike in men, evidence for CPAP impact on sexual dysfunction in women 766 
is lacking346. In this review we did not discuss the impact of OSA on pregnancy. 767 
OSA & Polycystic Ovarian Syndrome (PCOS)     768 
OSA is highly prevalent in women of reproductive age with PCOS. A recent systematic review and 769 
meta-analysis from our group ( 15 studies, n=568) showed that 36.1% (95% CI: 22.4-51.0) of women 770 
with PCOS had OSA regardless of the PCOS definition used347. In addition, OSA prevalence was 771 
significantly higher in obese women with PCOS compared to lean (OR: 3.96, 95%CI: 1.29-12.13) and in 772 
adult women compared to adolescents, both of which are expected since obesity and age are main 773 
risk factors of OSA, and thus PCOS precedes OSA development347. However, in this meta-analysis 774 
there was significant heterogeneity among studies, most studies came from the USA in women with 775 
obesity (class II) and there is a high level of selection bias since controls came from general 776 
population while exposed cohorts were recruited from specialised clinics347. It is plausible that in 777 
some cases the OSA could precede PCOS development as detailed in a recent study showing that 1/3 778 
of adolescent girls with PCOS had previous tonsillar enlargement/ tonsillectomy 348.  779 
It is also interesting that although androgens are considered to impact OSA pathogenesis, 780 
contributing to the higher OSA prevalence in women with PCOS, three studies showed that women 781 
with PCOS and increased androgens did not have higher prevalence of OSA compared to controls, and 782 
the relationship between OSA severity and hyper-androgonaemia were not consistent across the 783 
studies347. This could be due to the low circulating androgen levels in women with PCOS compared to 784 
men. 785 
In another meta-analysis from our group comparing women with PCOS and OSA vs women with PCOS 786 
only showed that the earlier group had higher BMI (mean difference: 6.01 kg/m2, 95% CI: 4.69-7.33), 787 
waist circumference (MD: 10.93 cm, 95% CI: 8.03-13.83), IR (HOMA-IR: MD=2.23, 95% CI: 1.41-3.06; 788 
I2=0%), systolic BP (10.8 mmHg 95%CI 6.21 – 15.39), diastolic BP (4.63 mmHg 95%CI 1.06 – 8.21), 789 
impaired glucose tolerance (2 hour plasma glucose on OGTT: MD=2.23, 95%: 0.67-2.11, I2=0%) and 790 
worse lipids profile (higher total cholesterol, LDL, and triglycerides and lower HDL) compared to the 791 
alter group349. The androgen levels were not different between the two groups but hirsutism was 792 
worse in the OSA group349. However, these studies included were relatively small, at high risk of 793 
selection bias, and did not account for important potential confounders such as obesity349. 794 
Several mechanisms link PCOS to OSA as summarised in Figure 9350.  795 
OSA & Bone metabolism 796 
Although cross-sectional studies assessing the relationship between OSA and bone mass density 797 
(BMD) showed conflicting results351-354; longitudinal studies showed an increased risk of osteoporosis 798 
in patients with OSA355, 356. In a large retrospective cohort study of 1377 patients with newly 799 
diagnosed OSA and 22655 matched controls (age, sex and index date), the risk of osteoporosis was 800 
greater in patients with OSA vs. control in both men and women (incidence rate: 2.52/1000 person-801 
years vs. 1.00/1000 person-years, adjusted HR 2.74, 95% CI: 1.69-4.44) over the 6-year follow-up355. 802 
The HR in this study was adjusted for: age, gender, diabetes status, obesity, CVD risk factors, CKD, 803 
CVD, gout, and social demographics.  804 
Consistent with the increased risk of osteoporosis in patients with OSA, several studies suggested that 805 
OSA might increase the risk of fractures, although these studies examined conditions that are related 806 
to OSA rather than OSA per se. In a study of 2911 men older than 67 years-old, men who spent ≥ 10% 807 
of their sleep time with O2 saturations < 90% had increased risk of incident non-spinal fractures 808 
compared to men spent < 1% of sleep time with O2 saturation < 90% over 7 years follow-up (adjusted 809 
relative hazards 1.42, 95% CI 0.94- 2.15, p=0.047)357. In the same study, the relative risk of having  ≥ 1 810 
fall was also higher in the group with nocturnal hypoxaemia (relative risk 1.25, 95%CI 1.04 – 1.51)357. 811 
Another longitudinal study that followed up 8101 women aged 69 years or older for 6 years found 812 
that self-reported daily napping was associated with increased risk of incident hip fractures compared 813 
to women who did not nap daily (age-adjusted HR: 1.29, 95%CI 1.02-1.65; fully-adjusted HR 1.33, 814 
95%CI 0.99-1.78) and similar to the previous study there was an increased risk of falls in women who 815 
napped daily 358. In a recent cohort study women (n=3220) and men (n=2969) aged 40 years and 816 
older, severe snoring (a common OSA symptom) was associated with increased risk of fractures over 817 
10 years follow up in women (adjusted HR: 1.68, 95% CI: 1.16-2.43, p=0.006), with similar non-818 
significant trend in men359. 819 
Consistent with the increased risk of osteoporosis and fractures in patients with OSA, bone resorption 820 
markers (such as serum C-terminal telopeptide of type I collagen CTX) has been shown to be higher in 821 
patients with OSA compared to controls in men and the AHI was independently associated with 822 
urinary CTX independently of age, BMI and other variables352, 360. Furthermore, CPAP for 3 months 823 
lowered the creatinine adjusted urinary CTX levels significantly (211±107 vs. 128±59 824 
μg/mmol/creatinine; p<0.01)360. 825 
Several mechanisms might explain the impact of OSA on bone turnover, bone density and fractures 826 
risk summarized in Figure 10  361-373. 827 
 828 
Summary and conclusion:  829 
 830 
In this review we have demonstrated that there are multiple bi-directional interactions between OSA 831 
and the endocrine system although the observed relationships varied depending on the endocrine 832 
system examined. The impact of OSA on the endocrine system was mostly mediated by intermittent 833 
hypoxaemia, sympathetic activation, the elevated blood pressure and the increased inflammation 834 
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and oxidative stress. While the impact of the endocrine system on OSA was mostly mediated via 835 
increased upper body adiposity, narrowing of the upper airways, weakening of upper airway muscles, 836 
changes to chemosensitivity and ventilatory drive as well as autonomic dysfunction.   837 
Our review also shows that there are multiple knowledge gaps in the field at a mechanistic level and 838 
also due to the lack of well-designed cohort and interventional studies in many areas. This is further 839 
complicated by the difficulty in achieving good compliance with CPAP in clinical studies, the diurnal 840 
nature of the endocrine system and the interaction between OSA and other sleep disorders such as 841 
short sleep duration and misalignment in the circadian rhythm. In particular, our review found the 842 
following need to be explored in future studies due to either no, minimal, or inconsistent evidence 843 
currently available:  the impact of OSA and CPAP on weight, the impact of Diabetes treatment on OSA 844 
as well as the impact of OSA on diabetes-related outcomes, the impact of primary aldosteronism 845 
treatment on OSA, the effects of OSA on the HPA axis and the natural history of OSA and its response 846 
to treatment in patients with Cushing’s syndrome, the long term impact of GH replacement on OSA as 847 
well as central SA, the impact of thyroxine replacement on OSA in patients with hypothyroidism, the 848 
relationship between OSA and subclinical hypothyroidism,  the impact of long term testosterone 849 
replacement and the different methods of replacement on OSA, the impact of OSA and CPAP in 850 
women with PCOS and men with hypogonadism, and the impact of CPAP on bone metabolism. 851 
Finally, clinicians treating patients with endocrine conditions should not assume that OSA would 852 
recover by curing the underlying endocrine disorder (such as Cushing’s, acromegaly or 853 
hypothyroidism) and that OSA status need to be clarified by formal testing following the successful 854 
treatment of the endocrine condition. Furthermore, clinicians, surgeons and anesthetists involved in 855 
the treatment of the endocrine conditions that are associated with OSA need to be aware of this 856 
association and treat the OSA in order to improve the safety of the general anaesthesia and surgical 857 
procedures. 858 
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Figures-Legends & text: 1994 
 1995 
Figure 1: Hypnograms and sleep stages of a healthy individual (top) and a patient with OSA (bottom). 1996 
Please note how the patient with OSA has disrupted sleep architecture with loss of REM and SWS.  1997 
REM: Rapid Eye Movement; SWS: Slow Wave Sleep 1998 
 1999 
 2000 
Figure 2: OSA & Obesity Interplay. A. The potential mechanisms linking obesity to obstructive sleep 2001 
apnoea. B. The potential impact of obstructive sleep apnoea and its treatment on weight and the 2002 
underlying mechanisms. Red boxes are the mechanisms of OSA that might lead to weight gain; Dark 2003 
blue boxes are the mechanisms of possible weight loss in OSA.  2004 
UA: Upper Airways; TNF-A: Tumour Necrosis Factor- Alpha; IL-6: Interleukin-6; CNS: Central Nervous 2005 
System; EDS: Excessive Daytime Sleepiness; CPAP: Continuous Positive Airway Pressure 2006 
 2007 
Obesity can lead to increased UA collapsibility via increased parapharyngeal fat deposition, UA 2008 
narrowing, intramuscular fatty deposits leading to reduced UA muscles activity and increased UA 2009 
muscle fatigability, and reduced lung volume resulting in reduced tracheal caudal traction
19-27
. In 2010 
addition, the low lung volume in obesity can lead to hypoxaemia and ventilatory instability in the 2011 
presence of increased whole body oxygen demand due to obesity (high loop gain) 
28
. Obesity is also 2012 
associated with leptin resistance, which could inhibit the respiratory drive as leptin is a respiratory 2013 
stimulant 
23, 29-31
. Furthermore, visceral adiposity can affect the neural respiratory control and the 2014 
responsiveness of the chemoreceptors, through neurohormonal and inflammatory mechanisms (such 2015 
as (TNF)-a, and IL-6)
26, 30, 32
, but OSA itself can further worsen inflammation and possibly oxidative 2016 
stress, therefore, leading to a vicious cycle
23, 26, 33
. 2017 
 2018 
Figure 3: The potential bi-directional relationship and the underlying mechanisms 2019 
between obstructive sleep apnoea and Type 2 Diabetes.  SWS: Slow-wave-sleep; CB: Carotid 2020 
body; FFA: Free fatty acid; ROS: Reactive oxygen species; NAFLD: Non-Alcoholic Liver Disease; 2021 
HPA: Hypothalamic Pituitary Adrenal Axis; T2D: Type 2 Diabetes 2022 
 2023 
IH and sleep disruption result in increased oxidative stress and inflammation leading to IR an β- cell 2024 
dysfunction. In addition, OSA can impact multiple hormones that can lead to dysglycaemia including: 2025 
via activation of the Hypothalamus-pituitary- adrenal (HPA) axis, changes in the Growth hormone 2026 
(GH)/IGF axis, hyperaldosteronism (via hypokalaemia, increased oxidative stress and inflammation), 2027 
increased ghrelin, increased leptin and reduced adiponectin
40, 48, 90-95
. Interestingly, CPAP treatment 2028 
can interrupt most of the above mentioned pathways which might explain the favourable effects of 2029 
CPAP on IR
96
. However, the impact of CPAP on leptin and adiponectin has not been consistent 2030 
between the different studies
97-101
. Furthermore, patients with OSA (due to recurrent microarousals, 2031 
the loss of SWS and the IH
59
 )  have increased sympathetic activity which can contribute to the 2032 
increased IR 
30, 102
. Several factors contribute to the sympathetic overactivation in OSA including the 2033 
recurrent microarousals, the loss of SWS and the IH
59
. The IH, via oxidative stress and its impact on 2034 
HIF signaling, results in carotid body chemosensory reflex and hence to increased sympathetic activity 2035 
103
, that is reversible by CPAP
104, 105
. Another mechanism that links OSA to dysglycaemia is the 2036 
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increased risk of Non-alcoholic fatty liver disease (NAFLD) and progression to steatosis in those 2037 
patients, due to ectopic fat accumulation and hepatic inflammation, with subsequent effects on 2038 
insulin sensitivity
106, 107
. A recent meta-analysis of nine cohort studies showed that OSA was a 2039 
predictor of the development and progression of NAFLD (based on liver enzymes and histology)
107
.    2040 
  2041 
 2042 
On the other hand, dysglycaemia could lead to OSA. One plausible mechanism in patients with pre-2043 
diabetes or diabetes is autonomic neuropathy, which might impact on UA innervation
6
, ventilatory 2044 
drive and central respiratory responses to hypercapnia
109, 110
. In addition, T2D is associated with 2045 
reduced pulmonary volumes  (forced vital capacity FVC, Forced Expiratory Volume in the first second 2046 
FEV1 and vital capacity VC) and functions compared to healthy individuals which could affect UA 2047 
stability
111-121 
. A meta-analysis of cross-sectional studies showed that diabetes is associated with a 2048 
modest but significant impairment of pulmonary function (in restrictive pattern)
122
  and diffusion 2049 
capacity for carbon monoxide
112, 113, 122, 123
. The impact of T2D on the lungs seems to be related to the 2050 
severity of hyperglycaemia independently of obesity and smoking
123
; which raises the possibility that 2051 
improvements in glycaemic control might have a favourable impact on OSA but this needs to be 2052 
examined. Furthermore, treatment intensification in patients with T2D is often associated with 2053 
weight gain
124
, which could lead to the development or worsening of OSA 
10, 125
. Other independent 2054 
predictors of incident witnessed apneas such as HOMA-IR, hypertriglyceridaemia, and smoking are 2055 
also common in patients with T2D and thus can have a negative impact on OSA
6, 108
.  2056 
 2057 
Figure 4: A. Mechanisms relating obstructive sleep apnoea to cardiovascular disease (A) 2058 
and microvascular complications Adapted from  Jullian-Desayes et al. with permission (B) in 2059 
patients with Type 2 diabetes. Adapted from Tahrani et al. with permission. CRP: C-reactive 2060 
protein; IH: intermittent hypoxia; NO: nitric oxide; NOx: total nitrate and nitrite; OSA: obstructive 2061 
sleep apnea; PKC: protein kinase C; AGE: advanced glycation end product; PARP: poly ADP ribose 2062 
polymerase; AR: aldose reductase; GAPDH: glyceraldehyde 3-phosphate dehydrogenase. 2063 
Fig. 4.A. Obstructive sleep apnea and its cardiometabolic consequences.. Adapted from Kohler et al., 2064 
2010 and Lavie et al., 2009 
140
 . IH, oxidative stress and inflammation play a key role in OSA and the 2065 
development of associated cardiometabolic morbidities. Oxidative stress induces inflammation, while 2066 
increased proinflammatory cytokines, adhesion molecules and procoagulant activities can exacerbate 2067 
oxidative stress. This vicious circle leads to cardiovascular morbidity. Sympathetic overactivity and the 2068 
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decrease in NO induced by oxidative stress lead to hypertension. Both hypertension and 2069 
inflammation promote endothelial dysfunction responsible for atherosclerosis, which in turn can also 2070 
exacerbate oxidative stress
 140
. In addition, intrathoracic pressure swings and the increase in 2071 
transmural pressure gradients over vessel walls could also contribute to the endothelial dysfunction 2072 
observed in OSA. Recurrent arousals also activate the sympathetic nervous system and thus lead to 2073 
endothelial dysfunction
 140
 .  2074 
Fig. 4.B. Both OSA and hyperglycaemia share similar molecular consequences including oxidative 2075 
stress, PKC activation and AGE production. Our own work has shown that patients with OSA and type 2076 
2 diabetes have increased oxidative and nitrosative stress increased PARP activation and impaired 2077 
microvascular function compared with patients with type 2 diabetes only
141
.  2078 
 2079 
Figure 5: The potential bi-directional relationship between obstructive sleep apnoea and 2080 
Hyperaldosteronism and the plausible linking mechanisms. IH: Intermittent hypoxia; RAAS: 2081 
Renin-angiotensin-aldosterone system; RH: resistant hypertension;  PA: primary aldosteronism;  2082 
MR: mineralocorticoid receptors. 2083 
 2084 
In rodent studies, IH promoted angiotensin I and AT1 expression, increased the activation of the 2085 
carotid body by Angiotensin II and resulted in increased renin and aldosterone levels leading to 2086 
increased BP
169, 170,159
. In addition, oxidative stress has been shown to increase the activation of the 2087 
mineralocorticoid receptors (MR) in rodent models
171
. Whether OSA is associated with renin 2088 
activations remains to be explored by further better designed studies of larger sample size as the 2089 
current studies show a non-significant trend.  2090 
The plausible mechanisms for the increased risk of OSA in patients with hyperaldosteronism are is 2091 
plausible due to the increased sodium and fluid retention resulting in UA oedema, increased UA 2092 
resistance and collapse
159, 176-178
. This might have been worsened further by increases in neck 2093 
circumference and oedema due to fluid displacement during recumbency overnight particularly in 2094 
patients with RH
159, 178
, which is supported by a study showing a reduction in neck circumference with 2095 
improvements in AHI after treatment of PA with either MR antagonist or adrenalectomy
172
.  2096 
 2097 
Figure 6: OSA & HPA axis dysregulation A. Possible underlying mechanisms  linking OSA to 2098 
HPA axis dysregulation  B. Possible mechanisms linking hypercortisolism with OSA development  2099 
CRH: Corticotropin Releasing Hormone, ACTH: Adrenocorticotropic hormone 2100 
 2101 
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Figure 7: OSA & GH/IGF axis. A. Possible underlying mechanisms for OSA leading to GH/IGF 2102 
axis dysregulation. B. Possible mechanisms linking GH excess (red arrows) and GH deficiency 2103 
(blue arrows) with OSA development. 2104 
The main causal mechanisms linking acromegaly to OSA are related to the anatomical changes that 2105 
occur as a result of GH excess leading to narrower and more collapsible UAs. Patients with 2106 
acromegaly have vertical growth of the mandible, which leads to pharyngeal obstruction due to the 2107 
retroposition of the tongue base with caudal displacement of the hyoid
225
. In addition, soft tissue 2108 
thickening/swelling, secondary to increased glycosaminoglycan deposition, collagen and tissue 2109 
oedema, and macroglossia contribute to the compromise of UAs in patients with acromegaly
226-234
. 2110 
This is supported by a study using MRI and nasopharyngoscopy that showed the tongue base and 2111 
uvula to be the main site of UA obstruction in patients with OSA and acromegaly
216
. In addition, the 2112 
uvula diameter correlated to the severity of the UA collapse and tongue measurements correlated to 2113 
the AHI and IGF-1 levels
216, 230
. The weakness of UA muscles (sternohyoid muscle) also contributes to 2114 
the increased risk of UA collapsibility in patients with acromegaly
235
. Other factors include 2115 
hypothyroidism, large goiters (detailed later)
219, 236, 237
, insulin resistance and dysglycaemia
219, 224, 238
.   2116 
 2117 
Figure 8: Mechanisms linking OSA and Hypothyroidism 2118 
Hypothyroidism can lead to increased UA collapsibility due to soft tissue swelling (in tongue, neck, 2119 
and pharynx) caused by mucopolysaccharides infiltration (myxoedema in the more severe form) 
256
. 2120 
In support of this mechanism, LT4 treatment reduced soft tissue swelling and improved AHI, 2121 
nocturnal hypoxaemia and sleep architecture in an uncontrolled study
254
.  Goitre (regardless of 2122 
thyroid status) can cause UA obstruction and collapse 
256, 263
. It causes narrowing of the UA by direct 2123 
mechanical obstruction, especially in supine position, and by increasing laryngeal oedema due to 2124 
reduced venous return; both of which can be resolved following thyroidectomy or LT4 in some 2125 
cases
256, 264-266
. Hypothyroidism (especially when severe) can also result in blunted ventilatory drive 2126 
and impaired chemosensors’ response to hypoxia/ hypercapnia in animal and human studies 
256
. This 2127 
is possibly due to decreased dopamine receptor (D1) expression in the brain stem and the CB in 2128 
rodents with hypothyroidism
267
, and can be reversed with LT4 treatment
256
. 2129 
Impaired UA dilator muscle function in hypothyroidism, due to altered myosin heavy chain expression 2130 
in rodent studies and neuropathy in humans, has also been reported 
217, 268
. Furthermore, the 2131 
diaphragm has been shown to be weaker in rodents and human studies in hypothyroidism, which 2132 
result in a reduction in lung volumes contributing to OSA development/worsening 
253, 256, 269
. The 2133 
diaphragm weakness can be improved by LT4 treatment
253
. Finally, obesity could be potentially 2134 
another link between OH and OSA as studies have shown that patients with OH are about 5-7kg 2135 
heavier compared to euthyroid matched-controlled
270
. However, this weight-increase in OH seems to 2136 
be related to expanded water compartment rather than fat mass. In addition, LT4 treatment causes 2137 
weight loss by reducing lean mass rather than fat mass (based on DXA)
271, 272
.    2138 
 2139 
 2140 
Figure 9: Obstructive Sleep Apnoea and Polycystic Ovary Syndrome; clinical interactions 2141 
and underlying pathophysiology.  Adapted from  Kahal et al. with permission. 2142 
Sex hormones are thought to play a role in this bidirectional relationship, as in women with PCOS 2143 
androgens excess along with lower progesterone (as a result of anovulation) can increase UA 2144 
collapsibility and/ or lead to blunted ventilator chemo-responsiveness
322
. While, IH and sleep 2145 
fragmentation can impact HPG axis and can influence GnRH and gonadotropins pulsatility, leading to 2146 
causing/ or worsening PCOS phenotype
322
. In addition, IR and dysglycamia in women with PCOS can 2147 
contribute to worsening or the development of OSA; 
322
. Obesity is common in both disorders and can 2148 
contribute to the associations between OSA and PCOS. Other common comorbidities are oxidative 2149 
stress, endothelial dysfunction and sympathetic activation all of which can lead to a vicious cycle of 2150 
OSA and PCOS entities
322
. 2151 
 2152 
Figure 10: OSA & Bone metabolism.  2153 
GH: Growth hormone, PTH: Parathormone, BMD: Bone mineral density, BRMs: Bone Resorption 2154 
Markers 2155 
As with other endocrine consequences of OSA, hypoxaemia plays an important role as has been 2156 
shown by Cauley et al and IH in human cell cultures and rodents can increase osteoclasts and inhibit 2157 
osteoblasts’ growth and differentiation via HIF transcription factor family (HIF-1a and HIF-2a) and 2158 
VEGF 
333-337
. In addition, IH can result in increased inflammation and oxidative stress that can lead to 2159 
higher risk of osteoporosis and fractures
338-340
. Other mechanisms including hyperleptinaemia and 2160 
sympathetic activation increase bone resorption and inhibit bone formation leading to bone mass 2161 
loss
341, 342
. Changes in melatonin profile could also contribute to the impact of OSA on bones, as 2162 
patients with OSA might have changed melatonin profile and lower melatonin serum levels compared 2163 
to people without OSA due to frequent nocturnal awakening and light exposure 
343
. Melatonin has 2164 
Formatted: Not Highlight
been shown to increase bone mass density in a RCT 
344
. Furthermore, serum 25-hydroxyvitamin D was 2165 
found to be lower (: 19.34 ± 9.54 ng/ml  vs. 32.83 ± 16.93 ng/ml, p < 0.0001) and PTH levels higher (: 2166 
62.57 ± 29.97 pg/mL vs. 40.05 ± 31.12 pg/mL, p < 0.0001) in patients with OSA compared to healthy 2167 
controls
345
. CPAP for 7 nights increased 25-hydroxyvitamin D concentrations ( 19.21 ± 9.45 vs. 21.03 ± 2168 
9.50, F = 8.32, p < 0.01) but had no effect on PTH
345
. The suppression of the gonadal axis and GH in 2169 
OSA and the associated insulin resistance could also contribute to the impact of OSA on bone 2170 
metabolism 
342
. T2D in particular can have detrimental effects on bone mass and fracture risk 374-377, 2171 
and as OSA increases the risk of T2D, then T2D is a potential mechanism between OSA and bone 2172 
disease. 2173 
 2174 
Formatted: Not Highlight
Field Code Changed
Formatted: Not Highlight
Formatted: Not Highlight
Figure 1
AB
OSA
-EDS, fatigue, sedentary behavior
-increased appetite (↑Ghrelin, Leptin resistance)
-High-calorie food intake & restraint loss due to 
Sleep disruption
-↑ Cortisol
-↑CO2
↓energy expenditure
↑energy intake 
Adipogenesis
Weight 
gain
↑ Sympathetic activity:     
↑energy expenditure 
& lipolysis
Weight 
maintenance/loss
CPAP
↓Sympathetic activity:
↓Energy Expenditure
↓Lipolysis
↓Leptin
OBESITY → → → OSA
-UA fat deposition        
-UA muscle impairment
-Abdominal fat
-high loop gain
-Leptin resistance
-UA narrowing
-↓ functional residual capacity 
-↓Tracheal traction
-increased UA collapsibility
- impaired ventilation
Inflammatory state:
↑ (TNF)-A, IL-6
Depression of CNS activity & 
UA neuromuscular control
↑Oxidative stress
↑↑Cytokines
Figure 2
Figure 3
REF: Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: a
systematic review from sham CPAP randomized controlled trials. Jullian-Desayes I, Joyeux-Faure M, Tamisier R, Launois S, Borel
AL, Levy P, Pepin JL. Sleep Med Rev. 2015 Jun;21:23-38. doi: 10.1016/j.smrv.2014.07.004. Epub 2014 Jul 31. (Permission needed)
Figure 4. A
Figure 4. B 
REF: Obstructive Sleep Apnoea and Type 2 Diabetes. Abd A Tahrani1 and Asad Ali2. European Endocrinology, 
2014;10(1):43–50  (Permission needed)
Figure 4
A.
Figure 4
B.
Figure 5
↑Salt 
intake
Positional 
nocturnal Fluid 
shift
Oxidative stress
Sympatho-excitation
OSA
RAAS 
activation
Aldosterone 
excess
RH
-↑Sympathetic tone
-Oxidative stress
-Inflammation
-Endothelial dysfunction
-Vascular stiffening
↑AngI, ↑AngII
Na+ & Fluid 
retention
Parapharyngeal 
edema
↑UA 
resistance
UA collapse
MR antagonist
CPAP
CPAP
PA
Vasoconstriction
↑ Na+ & water 
renal reabsorption 
CPAP
IH
↑MR 
Activation
Figure 6
Obstructive
Sleep 
Apnoea
HPA
Axis (up) 
dysregulation
➢ Night awakenings
➢ Sleep restriction
➢ Intermittent hypoxia
➢ Autonomic activation
Hypercortisolism
(Cushing’s s.) OSA
➢ Obesity
➢ Hyperglycaemia
➢ UA fat deposition
➢ UA myopathy
A.
B.
➢ ↑CRH release
➢ ↑ACTH
responsiveness
➢ ↑ pulsatile cortisol 
release
GH excess 
(acromegaly)
GH 
deficiency
➢ Craniofacial changes
➢ Soft tissue enlargement
➢ Thyroid disorders
➢ Dysglycaemia
➢ UA dilator muscle impairment 
➢ Adiposity
OSA
UA 
narrowing  & 
collapse
B.
Obstructive
Sleep
Apnoea
➢ Intermittent Hypoxia
➢ Sleep Fragmentation
➢ Obesity 
GH axis 
dysregulation
(↓GHRH, ↓GH, ↓IGHF-1, 
↓IGFBP-3)
A.
➢ Impaired somatotroph function
➢ Impaired peripheral GH sensitivity
➢ ↓GH mRNA expression
➢ SWS loss
➢ Insulin resistance
Figure 7
Figure 8
UA Tissue 
swelling
Goitre
UA muscles 
impairment
Weak diaphragm ↓Chemosensitivity
UA obstruction
↑UA collapse
↓Ventilation
Hypothyroidism
OSA
Figure 9
Ref:Hassan Kahal, Ioannis Kyrou, Abd A. Tahrani, Harpal S. Randeva . Obstructive sleep apnoea and polycystic ovary syndrome: A 
comprehensive review of clinical interactions and underlying pathophysiology. Clin Endocrinol (Oxf). 2017 Oct;87(4):313-319. doi: 
10.1111/cen.13392. Epub 2017 Jul 14. (Permission needed)
Figure 10
OSA
Intermittent 
hypoxia
Sympathetic 
stimulation
↑Leptin
↓Melatonin
↓Vit. D
↑PTH
Hypogonadism
↓GH
Osteoporosis & 
Fracture
Insulin 
resistance
T2D
Bone mass loss
↓Osteoblast &
↑Osteoclast
stimulation
↓BMD, ↑BRMs 
↑inflammation 
and oxidative 
stress 
Online Supplement  
OSA overview  
OSA pathogenesis  
Although the upper airway (UA) consists of rigid, cartilaginous structures, its patency can be 
compromised along a soft segment extending from the hard palate to the larynx (the 
pharynx), which allows the UA to change shape for speech and swallowing during 
wakefulness 1-3. However, in the presence of anatomically compromised upper airways 
(UAs), as in patients with OSA, the loss of wakefulness inputs to the control of the UAs and 
chest wall muscle motor neurons during sleep, produce UAs obstruction4. The underlying 
mechanisms driving these UAs obstructions are complex and multi factorial (Figure 1 of the 
online supplement).   
Patients with OSA have narrower UAs5, 6 with enlarged surrounding soft tissues compared to 
healthy controls; thus increasing the risk of collapse during sleep (Figure 2 of the online 
supplement)7-11. During wakefulness, the UA dilator muscles (genioglossus most studied) 
activity  is increased in patients with OSA, compared to healthy controls, compensating for 
the anatomically diminished UA size; while during sleep the UA dilator muscles activity is 
greatly reduced leading to pharynx collapse and subsequently UA obstruction, particularly 
during rapid-eye-movement (REM) sleep 1, 2, 12, 13. This reduction in UAs muscle tone during 
sleep is due to a combination of central lack of respiratory drive and local inhibitory reflexes 
that respond to changes in pressure in the UAs1. The chemoreceptors are also less 
responsive to PaO2 and PaCO2 changes during sleep
14, resulting in a reduced input to the 
respiratory centers in the brainstem and reduced UA dilators activity15-17. Even very small 
and transient reductions in PaCO2 can result in significant apnoea due to the changes in 
chemoreceptors activity during sleep4. The reduced UA dilator muscles activity is also due to 
reduced mechanoreceptors’ responses to changes in negative UA pressure (genioglossus 
negative pressure reflex18, 19) during REM.  
Respiratory arousal threshold (RAT) also plays an important role in the pathogenesis of OSA 
in some patients20. In response to changes in gas exchange, pH, lung volumes or UAs 
resistance, the respiratory centres in the brainstem can increase respiratory effort, which 
triggers an arousal from sleep when RAT is reached2, 21. Hence, arousals are protective as 
they increase UA muscle tone (similar to the awake state) and finally open obstructed UAs1. 
However, low RAT can have detrimental effects in patients with OSA as more frequent 
arousals can result in a disruption in sleep architecture and in restoring airflow before the 
development of adequate ventilatory drive and result in ventilatory overshoot associated 
with the sleep/wake transition leading to further obstructive episodes1, 2, 20-23.   
Another important element in OSA development is the ventilatory control stability, known as 
loop gain, which refers to the size of a “ventilatory correction” as a response to a 
“ventilatory disturbance”2, 24. Accordingly, in case of a high loop gain, small decrease in 
breathing will lead to a large correction. In the case of OSA, the loop gain appears to be 
elevated25, suggesting high responsiveness of the ventilatory system to disturbed breathing 
with a propensity to develop cyclical fluctuations in breathing output and increased response 
to arousal by hyperventilation driving PaCO2 below the apnea threshold
1, 26, 27.      
There are multiple other factors that contribute further to the pathogenesis of OSA and UA 
collapsibility including low lung volume (resulting in lack of pharyngeal stretching), reduced 
UAs surface tension and UA oedema 2, 28-32.     
OSA risk factors  
Excess body weight is the main risk factor for OSA33. Weight gain of 10% is associated with a 
6-fold higher risk of moderate to severe OSA development34. Similarly, 9% weight loss in 
patients with obesity and OSA results in 47% reduction in apneas frequency35 and 60% 
reduction in the Apnoea- Hypopnoea index (AHI) after 17% drop in BMI36. Men have 
consistently been shown to be at a 2- to 3-fold higher risk of OSA compared to women37; 
possibly due to differences in sex hormones which will be detailed later. Multiple studies 
showed African-Americans to be at increased risk of OSA compared to White Caucasians38-40. 
Whereas, differences in the prevalence of OSA in Asians vs. white Caucasians were 
inconsistent across multiple studies38, 41, 42. The ethnic variations could be related to 
differences in UA anatomy, respiratory arousal thresholds, fat distribution, genetic and 
environmental factors37, 43-45.  Prevalence of OSA increases with increasing age33, being 2-3 
fold higher in older people (≥65y), reaching eventually a plateau after the age of 6537. Other 
risk factors include smoking, excess alcohol intake, nasal obstruction and menopause37.  
OSA clinical features  
Snoring is the most frequent OSA symptom symptom but it is not diagnostic for the disease, 
as most snorers don’t have OSA and; only 6% of patients with OSA do not report snoring46, 
but it is very frequent in general population as well46. Other clinical features include, 
witnessed apneas, nightly chocking and gasping (reflecting an arousal after an apnea event), 
insomnia, nocturia, enuresis, arousals, sweating47, excessive daytime sleepiness (EDS), and a 
variety of other daytime symptoms such as fatigue, memory loss, irritability, morning 
headaches, depression, and erectile dysfunction46, 48.   
 
OSA comorbidities and associations:  
OSA is associated with significant comorbidities such as hypertension, Type 2 diabetes, 
cardiovascular disease, mortality, road traffic accidents, chronic kidney disease amongst 
others  4, 47, 49, 50.  
OSA diagnosis and treatment:  
Multiple definitions of OSA have been used in clinical research, which contributed to some of 
the variations in outcomes of studies in patients with OSA. OSA is generally diagnosed based 
on cut offs of parameters recorded during polysomnography or polygraphy. The AHI is 
defined as the average number of apnoea and hypopnea events per hour of sleep. The 
respiratory disturbance index (RDI) is defined as the AHI plus the respiratory-effort related 
arousals. The oxygen desaturation index (ODI) is the average number of oxygen desaturation 
per hour of sleep. The American Academy of Sleep Medicine (AASM) recommendations 
regarding OSA diagnosis and the criteria used to define apnoea and hypopneas are detailed 
here 51, 52.   
Polysomnography remains the gold-standard for diagnosing OSA, although multiple portable 
devices have also been considered appropriate if adequate channels are recorded according 
to the latest AASM guidelines52. Sleep staging is desirable but not always considered 
essential. CPAP is the gold standard treatment for patients with moderate to severe OSA in 
addition to weight loss in patients with obesity48, 53, 54. Intra oral devices can be used in mild 
OSA and more recently upper airway stimulation can also be used in certain patients groups 
55, 56.   
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Figures for the online supplement  
  
Figure 1: Summary of the pathogenesis of obstructive sleep apnoea (OSA). Pcrit: Critical 
closing pressure (The pressure inside the airway at which the airway collapses); PaCO2: Partial 
pressure of Carbon dioxide in arterial blood   
Ref: Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of Sleep Apnea. 
Physiol Rev 90: 47–112, 2010; doi:10.1152/physrev.00043.2008 (Permission needed)  
  
  
Figure 2: Upper airways size in patients with OSA and healthy individuals (top); and the 
 impact of sleep on upper airways size in a healthy individual (bottom).     
 
A: midsagittal magnetic resonance image (MRI) in a normal subject (left) and in a patient 
with severe OSA (right). Highlighted are the four upper airway regions (nasopharynx, 
retropalatal region, retroglossal region, hypopharynx) and upper airway soft tissue (soft 
palate, tongue, fat) and craniofacial structures (mandible). Fat deposits are shown in white 
on the MRI. Note that in the apneic patient: a) the upper airway is smaller, in both the 
retropalatal and retroglossal region; b) the soft palate is longer and tongue size is larger; and 
c) the quantity of subcutaneous fat is greater. B: state dependence of upper airway size in a 
normal subject as assessed via three-dimensional reconstructions of MRI images. Images 
represent averages taken over several respiratory cycles during eupneic breathing in sleep 
and wakefulness. Airway volume during NREM sleep is smaller in the retropalatal (RP) 
region, not in the retroglossal (RG) region. Such images show the marked effect of sleep, per 
se, on the loss of upper airway muscle dilator tone and also show that the upper airway does 
not narrow as a homogeneous tube during sleep.   
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